MX2022006676A - Nuevas moleculas para terapia y diagnostico. - Google Patents

Nuevas moleculas para terapia y diagnostico.

Info

Publication number
MX2022006676A
MX2022006676A MX2022006676A MX2022006676A MX2022006676A MX 2022006676 A MX2022006676 A MX 2022006676A MX 2022006676 A MX2022006676 A MX 2022006676A MX 2022006676 A MX2022006676 A MX 2022006676A MX 2022006676 A MX2022006676 A MX 2022006676A
Authority
MX
Mexico
Prior art keywords
synuclein
syn
disease
abnormality
disorder
Prior art date
Application number
MX2022006676A
Other languages
English (en)
Inventor
Marie Kosco-Vilbois
John Warner
Elpida Tsika
Romain Christian Ollier
Jan Peter Henning Stöhr
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of MX2022006676A publication Critical patent/MX2022006676A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a moléculas biparatópicas de unión al antígeno, tales como anticuerpos biparatópicos o fragmentos funcionales de los mismos, y mezclas que comprenden al menos dos anticuerpos monoespecíficos o fragmentos funcionales de los mismos, que pueden ser empleados para la prevención, alivio, tratamiento y/o diagnóstico de enfermedades, trastornos y anormalidades asociados con proteínas del CNS tal como alfa-sinucleína (a-sinucleína, A-sinucleína, aSinucleína, A-syn, a-syn, aSyn, a-syn), Tau, TDP-43, ASC, NLRP3, C5a, C1q, C3, huntingtina o proteína priónica. La presente invención se refiere además, al uso de moléculas de la invención para determinar una predisposición a un trastorno, enfermedad o anormalidad, monitorear el trastorno, enfermedad o anormalidad residual asociada con proteínas del CNS tal como alfa-sinucleína (a-sinucleína, A-sinucleína, aSinucleína, A-syn, a-syn, aSyn, a-syn), Tau, TDP-43, ASC, NLRP3, C5a, C1q, C3, huntingtina o proteína priónica, o predecir la sensibilidad de un paciente quién está sufriendo de tal trastorno, enfermedad o anormalidad al tratamiento con un cierto medicamento.
MX2022006676A 2019-12-04 2020-12-04 Nuevas moleculas para terapia y diagnostico. MX2022006676A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19213703 2019-12-04
EP20202412 2020-10-16
PCT/EP2020/084776 WO2021110995A1 (en) 2019-12-04 2020-12-04 Novel molecules for therapy and diagnosis

Publications (1)

Publication Number Publication Date
MX2022006676A true MX2022006676A (es) 2022-07-05

Family

ID=73748082

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006676A MX2022006676A (es) 2019-12-04 2020-12-04 Nuevas moleculas para terapia y diagnostico.

Country Status (8)

Country Link
EP (1) EP4069734A1 (es)
JP (1) JP2023504699A (es)
KR (1) KR20220110539A (es)
CN (1) CN115151562A (es)
AU (1) AU2020394842A1 (es)
CA (1) CA3159964A1 (es)
MX (1) MX2022006676A (es)
WO (1) WO2021110995A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4229082A1 (en) * 2020-10-16 2023-08-23 AC Immune SA Antibodies binding to alpha-synuclein for therapy and diagnosis
GB202203066D0 (en) * 2022-03-04 2022-04-20 Univ Swansea Anti-rage antibody
CN116023497B (zh) * 2022-11-09 2024-06-21 四川大学华西医院 抗ddr1抗体及其用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
EP0652775B1 (en) 1992-07-27 2000-04-19 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Targeting of liposomes to the blood-brain barrier
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
IL138801A0 (en) 1998-04-03 2001-10-31 Chugai Pharmaceutical Co Ltd Humanized antibody against human tissue factor and process for the preparation thereof
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6261790B1 (en) * 1999-07-15 2001-07-17 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies and antibody cocktail for detection of prion protein as an indication of transmissible spongiform encephalopathies
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
KR101111477B1 (ko) 2002-12-03 2012-02-23 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 치료제와 연결된 콜레스테롤을 포함하는 접합체
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
JP2007505142A (ja) 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
WO2006034488A2 (en) 2004-09-23 2006-03-30 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP2949666B1 (en) * 2008-12-19 2018-12-19 Biogen International Neuroscience GmbH Human anti-alpha-synuclein antibodies
CA2813833C (en) 2010-10-26 2020-09-22 Ac Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
WO2014008404A1 (en) * 2012-07-03 2014-01-09 Washington University Antibodies to tau
CN107074938A (zh) * 2014-10-16 2017-08-18 豪夫迈·罗氏有限公司 抗‑α‑突触核蛋白抗体和使用方法
SG11201906947SA (en) * 2017-02-17 2019-08-27 Bristol Myers Squibb Co Antibodies to alpha-synuclein and uses thereof
JOP20190227A1 (ar) * 2017-03-31 2019-09-30 Biogen Int Neuroscience Gmbh تركيبات وطرق لعلاج اعتلالات السينوكلين
WO2018237338A1 (en) * 2017-06-23 2018-12-27 Denali Therapeutics Inc. ANTI-ALPHA-SYNCUCIN ANTIBODIES AND METHODS OF USE
MX2020003145A (es) 2017-09-22 2020-07-29 Wuxi Biologics Ireland Ltd Nuevos complejos de polipeptidos biespecificos.
GB201720970D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies

Also Published As

Publication number Publication date
JP2023504699A (ja) 2023-02-06
WO2021110995A1 (en) 2021-06-10
CA3159964A1 (en) 2021-06-10
EP4069734A1 (en) 2022-10-12
KR20220110539A (ko) 2022-08-08
CN115151562A (zh) 2022-10-04
AU2020394842A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
MX2022006676A (es) Nuevas moleculas para terapia y diagnostico.
AU2019202459B2 (en) Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g
Cattepoel et al. Chronic intranasal treatment with an anti-Aβ30-42 scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease
Karam et al. Vitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosis
Matsumoto et al. CD44 expression in astrocytes and microglia is associated with ALS progression in a mouse model
EA201890313A1 (ru) Гуманизированные антитела к пироглутаматному варианту бета-амилоида
HRP20210680T1 (hr) POBOLJŠANA PROTUTIJELA KOJA VEŽU Aβ PROTOFIBRIL
MX2018010693A (es) Compuestos biciclicos para diagnostico y terapia.
MX2021012608A (es) Nuevas moleculas para terapia y diagnostico.
MX356800B (es) Anticuerpo tau humanizado.
Newsome et al. Stiff person syndrome spectrum disorders; more than meets the eye
PH12020552188A1 (en) Compositions and methods of inhibiting masp-2 for the treatment of various thrombotic diseases and disorders
MX2020006956A (es) Moleculas de union a tdp-43 mal plegadas.
EA201492162A1 (ru) Антитела к трансглютаминазе 2
EA202091629A1 (ru) Гуманизированные и деиммунизированные антитела
Mahdiabadi et al. Immune modulations and immunotherapies for Alzheimer’s disease: a comprehensive review
Winkler et al. Rapid cerebral amyloid binding by Aβ antibodies infused into β-amyloid precursor protein transgenic mice
Koryachkin Complex regional pain syndrome
MX2022002873A (es) Nuevas moleculas para diagnostico.
BR112022002142A2 (pt) Anticorpos anti-bdca-2
Shimojima et al. Analysis of peripheral blood lymphocytes using flow cytometry in polymyalgia rheumatica, RS3PE and early rheumatoid arthritis
Gupta et al. Immunotherapy in Alzheimer’s disease
Gόmez et al. AB0747 Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 9 patients
Azarion et al. Electrographic seizures persisting through pharmacologically induced burst suppression: a case of anti-gaba (b)-receptor limbic encephalitis
AR118788A1 (es) Moléculas para terapia y diagnóstico